225. Congenital nephrogenic diabetes insipidus
[
11 clinical trials,
35 drugs（DrugBank:
15 drugs),
30 target genes / 61 target pathways ]
Searched query = "Congenital nephrogenic diabetes insipidus", "Hereditary nephrogenic diabetes insipidus", "Nephrogenic diabetes insipidus"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCTs031180369 | 12/04/2018 | 10 September 2019 | Tolvaptan for nephrogenic diabetes insipidus | Exploratory study of tolvaptan use for nephrogenic diabetes insipidus caused by mutation in vasopressin type 2 receptor - Tolvaptan use for NDI by V2R mutation | Nephrogenic diabetes insipidus Nephrogenic diabetes insipidus, polyuria;D018500 | Starting tolvaptan from 60 mg and dose up to 90mg and 120mg in every 1 or 2 days. | Noriko Makita | Recruiting | 20age | not applicable | Both | 3 | Phase 1-2 | none | |
| 2 | EUCTR2016-001591-30-DK | 06/11/2017 | 23 July 2018 | Treatment of congenital nephrogenic diabetes insipidus with riociguat or sildenafil | Treatment of congenital nephrogenic diabetes insipidus with a guanylate cyclase stimulator, riociguat or a phosphodiesterase type 5 inhibitor, sildenafil | Nephrogenic diabetes insipidus because of AVP2R-mutation MedDRA version: 20.0 Level: LLT Classification code 10012626 Term: Diabetes nephrogenic (excludes glycosuria) System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Hormonal diseases [C19] | Trade Name: Adempas Product Name: Adempas Pharmaceutical Form: Tablet INN or Proposed INN: RIOCIGUAT CAS Number: 625115-55-1 Other descriptive name: RIOCIGUAT Concentration unit: mg milligram(s) Concentration type: up to Concentration number: 3- Trade Name: Viagra Product Name: Viagra Pharmaceutical Form: Tablet INN or Proposed INN: SILDENAFIL CAS Number: 139755-83-2 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 150- | Odense University Hospital | Authorised | Female: no Male: yes | 2 | Phase 2 | Denmark | |||
| 3 | NCT02967653 | July 13, 2017 | 16 December 2017 | Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus | Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled Trial | Lithium Use, Nephrogenic Diabetes Insipidus | Drug: Atorvastatin | Lady Davis Institute | Recruiting | 18 Years | 85 Years | All | 60 | Phase 2 | Canada | |
| 4 | JPRN-UMIN000021708 | 2016/04/18 | 5 November 2019 | A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. | A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. - A study to evaluate effect and safety of Tolvaptan in Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene. | Nephrogenic Diabetes Insipidus caused by mutations in the vasopressin type 2 receptor gene | Administration of Tolvaptan once per day (60mg/day, 90mg/day, 120mg/day), each dose for two days. | Department of Nephrology and Endocrinology, The University of Tokyo Hospital | Recruiting | 20years-old | Not applicable | Male and Female | 3 | Not selected | Japan | |
| 5 | NCT02460354 | September 2015 | 30 July 2018 | Metformin and Congenital Nephrogenic Diabetes Insipidus | Use of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI) | Diabetes Insipidus | Drug: Metformin | Emory University | Not recruiting | 18 Years | N/A | Male | 2 | Phase 1 | United States | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2012-001809-24-NL | 31/07/2013 | 5 August 2013 | A diminished concentrating ability of the kidneys due to lithium prescription: how many and whom is affected? | Evaluation of urinary concentrating defects in lithium treated patients with a dDAVP test - Nephrogenic diabetes insipidus (NDI) in lithium treated patients | lithium-induced urinary concentrating defects (nephrogenic diabetes insipidus) MedDRA version: 15.0 Level: LLT Classification code 10050501 Term: Lithium toxicity System Organ Class: 10022117 - Injury, poisoning and procedural complications MedDRA version: 15.0 Level: LLT Classification code 10012600 Term: Diabetes insipidus nephrogenic System Organ Class: 10038359 - Renal and urinary disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Trade Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses Product Name: Desmopressine nasal spray 10 mg/ml, flacon 60 doses Product Code: SUB21605 Pharmaceutical Form: Nasal spray, solution INN or Proposed INN: desmopressin acetate trihydrate CAS Number: 62357-86-2 Current Sponsor code: not applicable Other descriptive name: DESMOPRESSIN ACETATE TRIHYDRATE Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 0.1- | Radboud University Nijmegen Medical Centre | Authorised | Female: yes Male: yes | Netherlands | |||||
| 7 | EUCTR2011-005970-41-NL | 27/02/2012 | 14 January 2013 | The effect of the drug acetazolamide on excessive urine production due to a diminished concentrating ability of the kidney as a result of the use of lithium in patients with an affective disorder: a pilot study | The effect of acetazolamide on lithium-induced nephrogenic diabetes insipidus in patients with an affective disorder: a pilot study | lithium-induced nephrogenic diabetes insipidus MedDRA version: 14.1 Level: LLT Classification code 10012600 Term: Diabetes insipidus nephrogenic System Organ Class: 10038359 - Renal and urinary disorders MedDRA version: 14.1 Level: LLT Classification code 10050501 Term: Lithium toxicity System Organ Class: 10022117 - Injury, poisoning and procedural complications ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18] | Trade Name: Acetazolamide Sandoz 250 Pharmaceutical Form: Tablet CAS Number: 59-66-5 Other descriptive name: ACETAZOLAMIDE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 250- | Radboud University Nijmegen Medical Centre | Authorised | Female: yes Male: yes | Netherlands | |||||
| 8 | EUCTR2006-003360-56-DK | 28/08/2009 | 27 October 2014 | Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY | Farmakologisk behandling af CNDI – Et ”proof-of-concept” studie. - NDI-POC-STUDY | Kongenit nefrogen diabetes insipidus MedDRA version: 14.1 Level: PT Classification code 10068304 Term: Congenital nephrogenic diabetes insipidus System Organ Class: 10010331 - Congenital, familial and genetic disorders | Trade Name: Confortid Pharmaceutical Form: Tablet INN or Proposed INN: INDOMETACIN CAS Number: 53-86-1 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: Losec Pharmaceutical Form: Tablet INN or Proposed INN: OMEPRAZOLE MAGNESIUM CAS Number: 95382335 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 10- Trade Name: Viagra Pharmaceutical Form: Tablet CAS Number: 171599-83-0 Other descriptive name: SILDENAFIL CITRATE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Pharmaceutical form of the placebo: Capsule, soft Route of administration of the placebo: Oral use Trade Name: Miacalcic Pharmaceutical Form: Nasal spray CAS Number: 47931-85-1 Other descriptive name: CALCITONIN (SALMON) Concentration unit: IU international unit(s) Concentration type: equal Concentration number: 200- Pharmaceutical form of the placebo: Nasal spray Route of administration of the placebo: Intranasal use (Noncurrent) Trade Name: Spirix Pharmaceutical Form: Tablet CAS Number: 52-01-7 Other descriptive name: SPIRONOLACTONE Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- Trade Name: Esidrix Product Name: Esidrix Pharmaceutical Form: Tablet INN or Proposed INN: HYDROCHLOROTHIAZIDE CAS Number: 58-93-5 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25- | Dept. of Pediatrics, The Childrens Hospital, Denver | Not Recruiting | Female: no Male: yes | 40 | Denmark | ||||
| 9 | NCT00478335 | May 2007 | 19 February 2018 | Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus | Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus | Nephrogenic Diabetes Insipidus | Drug: sildenafil;Drug: calcitonin;Drug: hydrochlorothiazide/amiloride;Drug: indomethacin;Drug: Placebo for sildenafil;Drug: placebo for calcitonin | University of Colorado, Denver | University of Aarhus | Not recruiting | 5 Years | 25 Years | Male | 4 | N/A | United States;Denmark |
| 10 | EUCTR2006-001202-84-NL | 01/02/2007 | 19 March 2012 | Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI | Comparison of the action of amiloride and thiazide in the reduction of lithium-NDI in patients with affective disorders - Treatment lithium-NDI | Lithium-induced Nephrogenic Diabetes Insipidus MedDRA version: 9.1 Level: LLT Classification code 10012600 Term: Diabetes insipidus nephrogenic | Trade Name: Midamor Product Name: Amiloride Pharmaceutical Form: Capsule* Trade Name: Hydrochloorthiazide Product Name: hydrochloorthiazide Pharmaceutical Form: Capsule* | Radboud University Nijmegen Medical Centre | Authorised | Female: yes Male: yes | 50 | Netherlands | ||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT00004360 | September 1995 | 19 February 2015 | Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus | Diabetes Insipidus, Nephrogenic | Drug: chlorothiazide | National Center for Research Resources (NCRR) | Northwestern University | Not recruiting | 6 Months | 70 Years | Both | N/A |